Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025

Core Viewpoint - Co-Diagnostics, Inc. and CoSara Diagnostics Pvt. Ltd. are hosting a symposium on March 4, 2025, to raise awareness about HPV and its link to cancer, coinciding with International HPV Awareness Day [1][2] Group 1: Symposium Details - The symposium titled "HPV and Cancer: Exploring Advances in Prevention and Care" will feature speakers from Co-Dx, CoSara, and experts in cancer diagnostics and oncology from India [2] - The event aims to educate the public about HPV, reduce stigma, and empower individuals to take action against the virus [2] Group 2: Cancer Statistics and Impact - The National Cancer Institute estimates that high-risk HPV subtypes are responsible for approximately 5% of all cancers globally, including cervical cancer, which caused an estimated 350,000 deaths in 2022 [3] - About 94% of cervical cancer deaths occur in low- and middle-income countries (LMICs), where access to diagnostics, vaccinations, and screenings can significantly reduce mortality [3] Group 3: Co-Diagnostics' Initiatives - Co-Diagnostics is completing the assay development for its HPV multiplex test, designed to identify 8 high-risk HPV subtypes from cervical swab samples, aiming to provide an affordable screening tool for patients, especially in LMICs [4] - The CEO of Co-Dx emphasized the importance of early diagnosis in effective treatment and limiting the spread of HPV [5] - CoSara's Saragene® Human Papillomavirus-High Risk real-time PCR test has been cleared for use in India to detect high-risk HPV genotypes [5]